# Drivers and impact of the early silent invasion of SARS-CoV-2 Alpha

Benjamin Faucher[1], Chiara E. Sabbatini[1], Peter Czuppon[2], Moritz U.G. Kraemer[3,4], Philippe Lemey[5], Vittoria Colizza[1], Francois Blanquart[6], Pierre-Yves Boëlle[1], Chiara Poletto*[7]

[1]Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), F75012, France

[2]Institute for Evolution and Biodiversity, University of Münster, Münster 48149, Germany

[3]Department of Biology, University of Oxford, Oxford, UK

[4]Pandemic Sciences Institute, University of Oxford, UK

[5]Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium

[6]Center for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research University, Paris 75005, France

[7]Department of Molecular Medicine, University of Padova, 35121 Padova, Italy

*Corresponding author. Email : chiara.poletto@unipd.it

## Abstract

SARS-CoV-2 variants of concern (VOCs) circulated cryptically before being identified as a threat, delaying interventions. Understanding the drivers of such silent spread and its epidemic impact is critical to inform future response planning. Here, we integrated spatio-temporal records of international mobility, local epidemic growth and genomic surveillance into a Bayesian framework to reconstruct the early dissemination of Alpha out of the UK in the first three months after emergence. We found that silent circulation lasted from days to months and was logarithmically associated with sequencing coverage. Social restrictions in certain countries likely slowed down the seeding of local transmission by weeks, mitigating the negative consequences of late detection. Revisiting the initial spread of Alpha supports local mitigation at the destination in case of emerging events.

## Introduction

In December 2020, one year after SARS-CoV-2 emergence, the increased transmissibility and severity of the Alpha variant (Pango lineage B.1.1.7) prompted an international alert (*1*, *2*). Attempts to contain the variant in the UK, where it was first identified, were too late and its global dissemination led to a resurgence of cases and deaths in many countries. Sequences shared through GISAID (*3*) in real time provided records of the variant's international spread (*4*) and a number of studies predicted the first countries that would be invaded based on international travel from the UK (*5–7*). Still, observations were not in agreement with the expectations, and it soon became clear that the first Alpha detection in countries outside the UK occurred when the variant had been circulating silently in these territories for some time. For instance, the first case infected by the Alpha variant was identified on 25 Dec 2020 in France (*3*); yet, three weeks later, already 3% of the ~100,000 weekly reported COVID-19 cases were caused by the Alpha lineage (*8*). Late detection was also noted in Switzerland (*9*) and the USA (*10*, *11*).

Phylodynamics analysis and modeling studies revealed that silent spread occurred for early SARS-CoV-2 lineages and subsequent variants of concern (VOCs) (*12–20*). It sparked the debate around the utility of reactive interventions, since containment is ineffective if the virus is already spreading cryptically, but epidemic mitigation or delay may still be possible (*21*). Recent work addressed the minimal sequencing coverage for an effective response, and proposed tools for risk assessment (*22–26*). However, the complex interplay of factors determining silent propagation remains poorly understood. Indeed, SARS-CoV-2 VOCs emerged in a context of

changing patterns of genomic surveillance, international travel, population immunity, and local interventions. At the time of Alpha emergence in late 2020, genomic surveillance was highly variable and changed dramatically as countries increased their genomic surveillance capacity. It took months from the emergence to declaring Alpha a VOC (*2*). During this period the epidemiological context across many regions changed substantially. The efforts to control a substantial autumn pandemic wave impacted the rate of exportations of Alpha out of the UK and the chance to seed local transmission. This makes the emergence of Alpha a paradigmatic example to examine how spatiotemporal variations in sequencing coverage, local epidemic growth and international travel determine the duration and impact of silent spread.

**Results**

**Factors contributing to the spread of Alpha.**

The early spread of the Alpha variant in the UK occurred in the last quarter of 2020, in a context where a lockdown, from 5 Nov to 2 Dec 2020, reduced local transmission and the potential for international propagation (*27–29*). Air, train, Channel Tunnel and ferry passengers traveling out of the UK in this month had fallen up to 20% of that in September (Fig. 1A).

Over the same period, more than 200,000 sequences were submitted to GISAID from 73 countries, which allowed monitoring the spread of Alpha. We defined the date of first Alpha detection in each country as the date of collection of the first Alpha sequence submitted to GISAID. We hypothesized that sequences collected earlier but submitted at a later date resulted from retrospective surveillance and would misrepresent the routine screening effort. Sequencing coverage ranged over four orders of magnitude over countries: 59% of the cases reported in New Zealand over Sep-Dec 2020 were sequenced, but the median for all countries was only at 0.3%. As might be expected, the date of first detection of Alpha was earlier with higher sequencing coverage and more travelers from the UK (Fig. 1B). The UK was the only country to report the Alpha strain before Dec 1st, 2020, followed by Denmark (2 Dec 2020) and Australia (7 Dec 2020). The Alpha international alert on 18 Dec 2020, led to a rise in sequencing coverage (Fig. 1C), shorter collection-to-submission times for Alpha sequences than for others (27 days (CI [8,137]) vs. 52 days (CI [10,162]), Fig. 1D and fig. S1) and prioritization of sequencing of travelers from the UK (*4, 30*). Nineteen countries collected their first Alpha sequence the week following the alert and submitted it with a median delay of 9 days. In most of

these countries, the first case detected was a case imported from the UK (*31*).

**Fig. 1. Factors associated with the pattern of observed Alpha dissemination.** (**A**) Change in outbound international traffic from the UK over time. The 73 countries contributing to GISAID during 1 Sep 2020 - 31 Dec 2020 are shown as an example. Traffic is rescaled to the maximum value over the period. International traffic includes air-travel and estimated passengers via train, ferry and Channel Tunnel (*32*). Countries displayed in blue are the six countries analyzed in detail in the last subsection of the Results section. (**B**) Date of first detection, i.e. collection of the first Alpha sequence submitted to GISAID, for each of the 73 countries contributing to GISAID before 31 Dec 2020 according to the sequencing coverage and the international traffic (passengers/day) averaged over the same period. For each day, the sequencing coverage of a country is defined as collected SARS-CoV-2 sequences on GISAID - regardless of the date of submission - divided by reported cases. The dashed line indicates $y = -x$. (**C**) Cumulative number of countries with at least one Alpha submission plotted by the date of collection and date of

submission as indicated by the light and the dark area respectively. The black line shows the profile of the average rescaled sequencing coverage over time. In each country, the sequencing coverage was rescaled by the maximum over the period displayed in the plot to highlight the trend. Countries' rescaled time series are then averaged. For sake of visualization the sequencing coverage is here smoothed over a 2 weeks sliding window. The purple line indicates the date of Alpha international alert (18 Dec 2020). The black vertical line indicates the censoring date used in the analysis (31 Dec 2020). (**D**) Distributions of delay (in days) from collection to submission for Alpha and other sequences (non-Alpha), considering sequences collected outside the UK from December 2020 to mid-January 2021 and submitted up to June 2021. The full time evolution of the delay distribution for Alpha and non-Alpha is reported in fig. S1.

We developed the Alpha international dissemination model to fit the date of first detection and the corresponding date of submission in countries outside the UK before 31 Dec 2020. We used dates for 24 countries where the Alpha was detected during the period (including the UK) and accounted for no detection by statistical censoring. The key assumption of the model is that the hazard of submitting an Alpha sequence in a country outside the UK results from the dynamically changing incidence in the UK, outbound flows of travelers from the UK, sequencing coverage at arrival and the delay from collection to submission. Thus, we assumed that during the early dissemination period, the UK was the origin of the first detected traveling case in destination countries. Although a simplification, this is in line with earlier work showing that the UK was the main source of Alpha dissemination during the first three months, while other countries became more important at a later stage (*19*). Time-varying incoming travelers from the UK, sequencing coverage and collection-submission delays were derived from data for each country. Fitted parameters were the exponential growth rate in the UK before and after the beginning of the November lockdown and the increase in genomic surveillance among travelers compared to cases in the community in destination countries following the international alert. Details are given in the Materials and Methods section.

Observed dates of first detection and submission (Fig. 2A) and cumulative number of countries submitting an Alpha sequence (Fig. 2B) matched the model predictions. Portugal and Germany detected Alpha earlier than predicted by our model; there the delays from collection to submission were the longest (48 days for Portugal and 23 days for Germany, versus a median of 9 days in the other countries submitting Alpha). For Portugal, the long gap between the collection dates of the first and the second submitted sequences suggests retrospective investigation. The model predicted a median seeding date of the Alpha epidemic in the UK on 8 Sep 2020 (95% prediction interval [Aug 21, Sep 19]). Estimated doubling time of incidence in the UK was 4.2 days (95% crI [3.6, 5.3]) before 5 Nov 2020 and 10.6 days (95% crI [6.5, 22])

afterwards. Assuming for the reproductive ratio R=1+rT, with T the generation time interval at 6.5 days (*33*) and r the Alpha exponential growth in the UK, these estimates would be compatible with R= 2 .0 [1.8, 2.3] and R=1.4 [1.1, 1.65] before and after 5 Nov 2020. These values broadly agree with previous estimates, with a pattern of decreased transmission over time (*27–29*, *34*, *35*). With these estimates, the predicted trend of Alpha infections in the UK was in agreement with the observations (Fig. 2C) (*36*). The large number of countries reporting Alpha almost simultaneously in late December was explained by an estimated 50-fold (95% crl [12, 298]) increase of sequencing coverage among travelers compared to non-travel related cases following the alert, consistently with active search of Alpha cases among travelers and their contacts.

In a sensitivity analysis, results were found to be robust to a range of modeling assumptions - e.g. changepoints for the exponential growth of incidence in the UK, rate of detection of COVID-19 infections outside the UK, and incubation period among the others. Details are reported in the supplementary text.

**Fig. 2. Comparison between the international dissemination model and the data.** (**A**) Date of collection of the first Alpha sample submitted to GISAID and corresponding date of submission for the 24 countries submitting Alpha sequences before 31 Dec 2020. Data are shown by purple circles (collection) and green triangles (submission). Model output is indicated by gray circles (collection) and gray triangles (submission). The horizontal bars display the 95% prediction interval. (**B**) Model predicted cumulative number of countries submitting a first Alpha sequence to GISAID compared with observations. In panels A and B, the purple vertical line indicates the date of Alpha international alert (18 Dec 2020). (**C**) Alpha incidence in the UK (*36*) and model-predicted epidemic profile in the UK. Both model predictions and data are rescaled to the sum over the period considered to allow comparing the profiles of the curves. To account for testing delays model predictions are shifted right of one week.

**Fig. 3. Timing of first importation and silent spread as estimated by the international dissemination model.** (**A**) Cumulative number of countries with an Alpha introduction as predicted by the model. The quantity is computed from the median predicted date of introduction in each country. (**B** and **C**) Median date of first introduction for each country estimated by the model with 95% prediction interval. For each country, we report the date of first Alpha detection (i.e. collection of first submitted sequence) (light pink) and the date of the first ever collected Alpha sequence (dark pink) from the data. For El Salvador, Papua New Guinea and Madagascar, no Alpha sequence had been reported before June 2021.(**D**) Duration of silent spread in days vs sequencing coverage. Duration of silent spread is computed as the difference between the date of first detection in the data and the median date of first introduction as predicted by the model.

## Silent spread ranged from days to weeks

We next used the international dissemination model to predict the date of first introduction of Alpha from the UK to each country and the duration of silent spread, i.e. the duration of the time from the first introduction to the first detection of Alpha. We found that up to ~65 countries could have experienced the introduction of Alpha by the end of December, compared with the 24 countries that reported it (Fig. 3A). Our model predicted that the first introduction of Alpha in a country occurred up to 70 days earlier than the date of first Alpha detection (Fig.3, B and C). For instance, our model predicted that Alpha arrived 60 days earlier in Italy with an average sequencing coverage of 0.3% during the period, while it was only 15 days in Hong Kong with a sequencing coverage of 50%. Overall, the duration of the silent spread showed a logarithmic association with the average sequencing coverage (Fig. 3D). The estimated dissemination pattern is consistent with real-time projections based on air-travel (*5*). Early introductions in Denmark and the USA were also consistent with the result of phylodynamic analyses and retrospective surveillance (*10*, *11*, *37–39*). We found that the collection date of the first Alpha sample ever collected in each country (earlier than first detection in 34 countries because of retrospective surveillance) was within the range of first introduction predicted by the model but for Colombia.

## Local dynamics affected the impact of silent spread

We then focused on the spread of Alpha in six countries where national genomic investigations estimated the incidence of the Alpha variant in early January 2021: Denmark, France, Germany, Portugal, Switzerland and the USA. We used a stochastic model (autochthonous model A) (*40*) to simulate chains of transmission generated by infections introduced from the UK as predicted by the international dissemination model described above. The model used country-specific time-varying reproduction number, overdispersion in transmission, and a 60% transmission

advantage of Alpha over the wildtype (*27*, *28*, *41*). The model reproduced the incidence of observed Alpha cases with a case ascertainment fraction of ~50% (Fig. 4A), although incidence in the USA was underestimated, possibly due to heterogeneity in the different states. To test the robustness of these predictions, we used a second model with age-structure, temporal variation in social contacts due to restrictions, and the co-circulation between Alpha and wildtype that was calibrated and validated for France (*42*, *43*) (autochthonous model B) finding also in this case a good agreement.

Besides supporting our estimates of Alpha dissemination out of the UK, the reconstruction of local epidemics outside the UK allowed investigating the potential impact of silent spread in the six focal countries. The estimated Alpha cases as of 31 Dec 2020 broadly scaled with the international traffic connecting the country with the UK (Fig. 4B). Still, potential consequences of silent spread could only be gauged by taking into account changes in local transmission (Fig. 4C). For example, while the first detected case in Germany and Switzerland had been collected almost on the same day, the reproductive ratio $R_t$ in Germany had generally been larger than in Switzerland during December. Therefore, the seeding of transmission chains still active at the end of the year in Germany could take place well before the first detected case was collected for the first time in the territory, while in Switzerland ~50% of the transmission chains started after first virus detection (Fig. 4C). Overall, earlier seeding of active chains was associated with larger average $R_t$ over the period (Fig 4D), but not with the reduction in traveling (fig. S3). Therefore, our analysis suggests that low levels of local $R_t$ delayed the establishment of local transmission, potentially countering the consequences of late detection.

**Fig. 4. Local spread of Alpha in six destination countries.** (**A**) Model vs. empirical spread of Alpha for six destination countries outside the UK. In the main plot, the empirical estimates of Alpha cases are computed by multiplying the Alpha frequency resulting from virological investigations by the COVID-19 incidence reported in the country at the same date. Model estimates are obtained with the autochthonous model A (AM A in the plot) as described in the Material and Methods. Grey lines show ratios of case detection of 100%, 50% and 25% between observed and predicted. In the inset, the frequency of Alpha in France obtained from the autochthonous model B (AM B in the plot) is compared with the empirical data. In both panels, black error bars indicate the prediction interval over 500 stochastic simulations obtained with the median volume of Alpha introduction as predicted by the international dissemination model. Colored bars account for the variability in the output of the autochthonous models accounting for the upper and the lower limit of the prediction interval of the Alpha introductions as given by the international

dissemination model. For each country we report the date when the percentage of Alpha was determined. (**B**) Empirically estimated number of Alpha infections vs average international traffic. (**C**) Comparison between the date of first introduction as predicted by the international dissemination model (with credible intervals) and the seeding time of the transmission chains survived until 31 Dec 2020, predicted with the autochthonous model A (open circle: median, segment: 95% prediction interval). Colors indicate the effective reproduction number of the historical strain, $R_t$, computed from weekly mortality data of each country (Material and Methods). The star shows the date of first Alpha detection as a comparison. (**D**) Difference between the median delay of seeding predicted by the autochthonous model A and the same quantity in the reference case - i.e. when $R_t$ is the same in all countries and traveling fluxes do not change in time -, plotted against the median $R_t$ in the destination country. The median $R_t$ of the historical strain is computed from the median date of first introduction to the median date of seeding.

## Discussion

Genomic surveillance has been a major advancement to monitor the spread of SARS-CoV-2 after initial emergence. However, interpreting these data is complicated as they do not follow a pre-established and coordinated sampling design. Here, taking the initial Alpha spread as an example, we showed that all components of the highly heterogeneous epidemic context had to be taken into account for interpretation.

Previous studies focused on traveling flows to explain arrival of a first infection into a new country (*44–48*). Yet differences in genomic surveillance capacity, over four orders of magnitude across countries during Alpha emergence, profoundly affected the introduction-to-detection delay with an exponential decrease with sequencing coverage. Furthermore, extraneous events like the international alert further altered the speed of variant detection. These strong spatiotemporal changes in genomic surveillance partially masked the true pattern of Alpha invasion, to the point that the correlation between the dates of detection and the international traffic was poor in the first 24 countries reporting Alpha (spearman correlation 0.24, p= 0.3). Yet our analysis showed that traveling flows remained the main drivers of viral spread, in agreement with other works (*19*, *44*, *46*, *47*). A more uniform sequencing collection protocol would have provided a coherent view of Alpha propagation improving public health awareness and response. This highlights the importance of eliminating surveillance blind spots by increasing sequencing in countries with poor surveillance (*22*).

According to our model, Alpha was introduced in more than 60 countries before the international alert. The alert triggered heightened genomic surveillance worldwide (3), reinstated lockdown measures in the UK, and resulted in border screening and travel bans in countries connected to

the UK (*27–29*). However, international restrictions likely came too late to contain Alpha. A more rapid recognition of Alpha as a VOC could have advanced the response by health authorities to delay the establishment of Alpha during a time when vaccination became available in some countries (*21*). Delays in declaring a VOC were also observed for subsequent episodes (*19*). A lineage with important mutations can be identified relatively quickly if sequencing coverage is high enough (*22, 23, 26*), although the assessment of clinical risk is slower (*23*). Lineages have shown the ability to become dominant without any increase in fitness in particular epidemiological contexts (*49*), while others like Beta remained at low frequency despite mutations of clinical importance. This underlines the importance of the context for interpretation of new variants (*50*).

The growing Alpha epidemic in the UK allowed dissemination despite the drop in international traffic out of the UK and the social restrictions in many countries. For instance, while UK travelers to France dropped by 56% in November compared to September, the number of Alpha-infected travelers to France still grew from 1 to 10 daily over November 2020 according to our model. The lockdown implemented in France at this time likely did not prevent the establishment of local transmission because Alpha was more transmissible. Restrictions may however delay successful invasion, as was apparent from the in-depth analysis of the six destination countries: a lower local reproductive ratio delayed the seeding of local transmission chains following importations up to one month. Although with the same analysis we could not address the consequences of the decline in travel, we expect that when local transmission is limited by control measures, introductions from the country of origin contribute more substantially to the epidemic at destination (*20*). Therefore, limiting importations through border control could contribute to mitigation.

Following Alpha, other SARS-CoV-2 variants raised concern due to their rapid emergence and spread, namely Beta, Gamma, Delta, Omicron and its sublineages. Undetected introductions and silent spread were likely common to all variants, although the epidemic context progressively changed between 2021 and 2022. The rise in international mobility and social contacts accelerated the spread of Delta and Omicron (*19*). This has reduced the window for public health response requiring an intensification of virus genomic surveillance to enable authorities to identify variants in time. However the high costs and phasing out of the pandemic have now reduced our ability to detect future VOC emergence events.

Our study is affected by a number of limitations. First, sequencing coverage was computed at the country level and no distinction could be made for traveler vs. local cases. We dealt with this by allowing an increase in detection after the Alpha alert. Information on screening protocols and testing rate among travelers would have improved the analysis, however this is rarely available (*18*). Second, we analyzed here the period before 31 Dec 2020. This time window was long enough to cover the seeding from the UK to the destination countries and observe the consequent onset of local transmission. At the same time, the window is sufficiently short to assume in first approximation the UK to be the source of Alpha spread, before large epidemics in other countries became the dominant source of traveling cases. Extending the analysis to a longer period would require a more general framework that can be the subject of future work. Third, we have here defined the date of first Alpha detection in a country as the date of collection of the first sequence submitted to GISAID. Reporting of variants of interest to local public health authorities can be indeed more rapid than submitting the sequence to GISAID. Still, we acknowledge that this may depend on the country and stage of the invasion, e.g. before and after the alert. In addition, the public sharing of a variant's sequence enables the recognition of its presence in a given territory by a larger public, including health authorities and scientific community worldwide.

To conclude, by jointly modeling epidemic dissemination and observation based on GISAID submissions we have quantified Alpha silent spread in countries outside the UK unveiling its link with international travel and sequencing coverage. Our results show that the duration of Alpha silent spread varied from days to months. Strong spatiotemporal heterogeneities in surveillance provided a major obstacle to data interpretation. Still, restrictions in place in destination countries may have delayed the establishment of local transmission and partially mitigated the negative consequences of late detection and response. By the time a new variant is recognised as a potential threat, surveillance authorities of countries outside the variant source should be prepared for the variant being potentially already present in the territory. Enhancement in local screening and measures aiming at containing local transmission are thus key ingredients of a response plan.

**Materials and Methods**

Data

**GISAID records:** While we did not use any actual sequences in this study, from GISAID entries (*3*) we retrieved collection dates, submission dates, information on lineage (i.e. whether it was Alpha or not) and country for all human SARS-CoV2 sequences submitted between 15 Aug 2020 and 1 Jun 2021 included (n=1,735,675 downloaded on 2 Jun 2021). Data in GISAID originated from 144 countries, however only 73 countries had submitted sequences collected between September 2020 and December 2020. We used GISAID entries to determine the date of first submission of an Alpha sample in each country and the respective date of collection, the latter defined as the "detection date". We also computed the date of the first collection ever of an Alpha sample in each country, irrespective of the date submitted. Finally we determined the distribution of delays from collection to submission and the sequencing coverage from the number of sequences by country and date of collection (see below). For GISAID sequences missing a collection date (3%), we imputed the missing date with a date selected at random from the sequences with complete data submitted in the same week and country.

**COVID-19 cases and death data:** We retrieved the daily number of COVID-19 cases by country from the COVID-19 data repository hosted by the Center for Systems Science and Engineering at Johns Hopkins University (CSSE) (*51*) to compute the sequencing coverage. Incidence of Alpha cases in the UK was obtained from the "Variants of Concern: technical briefing 6 - Data England" report (*36*). We used the weekly deaths time series from the European Center for Disease Prevention and Control (*52*) (downloaded on 1 Jul 2021) to compute the time varying reproduction ratio in Denmark, France, Germany, Portugal, Switzerland and the USA .

**Travel Data:** Travel flow from the UK to destination countries was reconstructed combining air travel data, estimates of passengers via train, Channel Tunnel and ferries. We computed probabilities of travel assuming a catchment population of 36M for London airports. More precisely:

- Air travel data were obtained from the International Air Transport Association (IATA) (*53*). It comprised the monthly number of passengers outbound from English airports by country of destination. From the monthly data we computed an averaged daily flux of passengers over the month. For each country, we aggregated all passengers directed to the country and leaving from all airports of London. In the sensitivity analysis we considered all airports of England.

- Eurostar rail passenger numbers going each day to France, Belgium and the Netherlands were estimated as in (*32*), assuming a 95% reduction due to the COVID-19 pandemic.

- We used the monthly number of cars crossing the Channel Tunnel (*32*, *54*) to derive an averaged daily flux of passengers over the month. We assumed that 1.5 passengers travel on average for each car (*32*) and that the repartition of passengers among countries in continental Europe is the same as for trains.

- Numbers of passengers via ferries to France, Belgium, the Netherlands, Spain and Ireland were obtained by (*55*). We used monthly data to compute an averaged daily flux of passengers over the month.

**Virological investigation records:** Virological surveys were conducted in a number of countries in early January. Through bibliographic search and via social media we gathered the survey data for Denmark, France, Germany, Portugal, Switzerland, the USA.These surveys give an estimated frequency of Alpha infections for the cases detected a given day (or a given time period). We also gathered the daily number of detected cases at the day of the survey (or the midpoint of the time period) from the Google data aggregator. From these two numbers, we calculated the number of detected Alpha cases. In table S1 we report the source, the date of the survey, detected Alpha frequency, and the number of Alpha cases computed for each country.

Data processing

**Sequencing coverage:** The sequencing coverage was computed for each day and each country as the number of sequences collected after imputation divided by the number of cases. In Fig. 1C, we smoothed the sequencing coverage with a two-weeks sliding window to highlight the general trend.

**Delays from collection to submission:** We computed the collection-to-submission times in different ways before and after the Alpha alert on 18 Dec 2020. Before the alert, we hypothesized that Alpha sequences would be reported with the same time pattern as other sequences. We therefore computed a delay distribution by country and by date of collection using all GISAID sequences as $\pi_c(d; u) = \frac{n_{u+d,c}}{N_{u,c}}$ where $d$ is the delay, $N_{u,c}$ the number of

sequences collected on day $u$ in country $c$ and $n_{u+d,c}$ those submitted on date $u + d$. For sequences collected after the alert of 18 Dec 2020, we accounted for the different delay distribution for Alpha and other sequences. Due to the limited number of Alpha sequences collected outside the UK soon after the alert we aggregated all data collected outside the UK, thus defining an average Alpha delay distribution for all countries. We then used a 3-day smoothing time window, where length 3 was chosen as the best compromise to smooth out fluctuations without masking meaningful trends. We therefore computed $\pi_c(d; u) = \frac{n_{d+u}}{N_u}$ with $N_u$ the number of Alpha sequences collected between day $u - 1$ and $u + 1$, and $n_{u+d}$ the number of those sequences submitted after $d$ days. Delays from collection to submission are reported in Fig. 1D and fig. S1.

International dissemination model

We model the observed data consisting in date pairs $\{S_c, T_c\}$ by country, where $S_c$ is the date of first submission of an Alpha sequence to GISAID and $T_c$ the corresponding date of collection in country *c*. To do so, we first described incident Alpha infections in the UK at time *t* as exponentially growing with time according to $inc_{UK}(t) = \exp(\sum_{T_0}^{t} r(u))$, where $T_0$ is fixed at 15 Aug 2020 (*35*) and *r(t)* the daily exponential growth rate. $T_0$ corresponds to the date when the risk of emergence starts, fixed at August 15, 2020. Consistently with (*4, 31*) we assumed that the first case reported to GISAID in each country outside the UK is an imported case, infected in the UK but discovered abroad. Thus, we model the detection and sequencing in countries outside the UK without the need to model local variant growth. The daily exponential growth rate in the UK was considered as constant ($r_0$) up to 5 Nov 2020, when the UK entered a lockdown, and constant ($r_1$) afterwards. No change of slope and two changes of slopes (at 5 Nov 2020 and at 2 Dec 2020, beginning and end of the lockdown respectively) were also considered in the sensitivity analysis. In the UK, the number of Alpha sequences collected depended on incidence and the sequencing coverage as $\lambda_{UK}^*(t) = K_{UK}\, s_{UK}(t) \sum_{j=0}^{J} inc_{UK}(t - j)$ where $s_{UK}(t)$ is the

sequencing coverage on day $t$, $J$ the duration of incubation (taken as 5 days) and $K_{UK}$ the detection probability. We considered that one case out of 4 would be tested ($K_{UK} = 0.25$) (*56*).

In other countries, the expected number of sequences collected at time $t$ in country $c$ additionally accounted for traveling as $\lambda_c^*(t) = K_c\, p_c(t)/N\, s_c(t) \sum_{j=0}^{J} inc_{UK}(t-j)$, where $p_c(t)/N$ is the fraction of the population traveling from the UK to country $c$ on day $t$ with N=36M the population in the catchment area of the London airports and $s_c(t)$ the sequencing coverage in country $c$ on day $t$ and $K_c$ the fraction of imported infections being detected as COVID-19 cases. We assumed detection of imported cases to be higher than the detection of local cases, thus we used $K_c = 0.5$ ($> K_{UK}$) and we tested $K_c$ = 0.25 in a sensitivity analysis. Finally, we allowed for an increase in collection of Alpha sequences among travelers relative to others after the alert of 18 Dec 2020 due to increasing sampling of travelers from the UK (*4*, *31*) using a multiplicative factor $\gamma$. Therefore, the expected number of collected Alpha sequences on day $t$ is $\lambda_c(t) = \lambda_c^*(t)$ before 18 Dec 2020 and $\lambda_c(t) = \gamma\lambda_c^*(t)$ afterwards. Taking into account collection-to-submission time, the expected number of sequences submitted at time $t$ in country $c$ is therefore

$\alpha_c(t) = \sum_{u \le t} \lambda_c(u)\, \pi_c(t-u, u)$, and the probability that a sequence submitted on day $t$ was collected on day $u$, with $u \le t$, is $\lambda_c(u)\, \pi_c(t-u, u)/\alpha_c(t)$.

To write up the likelihood of observations, we considered that the model described the dynamics of collection and submission until the end of 2020. We assumed Poisson variability in the number of Alpha infections and computed the probability that an Alpha sequence is submitted on GISAID for the first time on date $S_c$ in country $c$ as

$P(S_c) = \exp(-\sum_{u<S_c} \alpha_c(u))(1 - \exp(-\alpha_c(S_c)))$. The log-likelihood of the data in the model was :

$$logL(\{r_0, r_1\}, \gamma; \{S_c, T_c\}) = \sum_{c:T_c \le D} \log(\alpha_c(S_c)) + \log(\lambda_c(T_c)\, \pi_c(T_c, t)/\alpha_c(S_c)) - \sum_c \sum_{T_0}^{S_c} \alpha_c(u)$$

where the first sum runs on countries where an Alpha sequences was submitted before date $D$ (= 31/12/2020) and the second runs in all countries. The summary of all fixed parameters and their values is reported in table S2.

The model likelihood was explored with a Metropolis-Hastings procedure. We used an Exp(0.1) exponential prior on the first exponential growth rate $r_1$, a N(0,1) prior on second growth rate $r_2$ to allow for negative growth and an Exp(0.01) prior for the increase in sampling $\gamma$ (Table S3). Unless stated otherwise, 3 chains were run in parallel for 100000 iterations, with the first 50000 discarded as burn-in, the second half was thinned (1 iteration every 25) for a final posterior sample of size 2000. Convergence of the chains was checked visually (fig. S2). Estimates and credible intervals for the fitted parameters are reported in table S4 (baseline values, first row).

We computed the predictive distribution for the date of detection given the actual travel and sequencing coverage as $F_c(t; p_c, s_c, K_c) = 1 - \exp(-\int_{T_0}^{t} \lambda_c(u; p_c, s_c)\, du)$ using the posterior sample and computed 95% prediction intervals from these samples.

We finally computed the model-predicted date of first introduction in country *c* as the distribution $F_c(t; p_c, 1, 1)$ in each country, assuming that 100% sequencing occurred (s=1) and all cases were detected (K=1).

We computed predictive distributions from the model using parameters taken in the posterior distribution as follows (where the "hat" notation corresponds to the estimated value) :

- Expected incidence in the UK: $inc_{UK}(t) = \exp(\sum_{T_0}^{t} \hat{r}(u))$

- Distribution of time of emergence in the UK :

$$P(T_e < t \mid T_e < T_{UK}) = 1 - \exp\left(-\sum_{T_0}^{t} \hat{r}(u)\right) / \left(1 - \exp\left(-\sum_{T_0}^{T_{UK}} \hat{r}(u)\right)\right)$$

- Cumulated distribution of date of first submission: $P(S_c \le t) = 1 - \exp(-\sum_{u \le t} \hat{\alpha}_c(u))$

- Cumulated distribution of date of first introduction : $P(I_c \leq t) = 1 - \exp(- \sum_{u \leq t} \hat{\lambda}_c^1(u))$

with $\lambda_c^1(t) = p_c(t)/N \sum_{j=0}^{J} inc_{UK}(t - j)$ the number of (detected and undetected) infections.

To visualize goodness of fit, we computed the cumulated number of countries submitting an Alpha sequence by date $t$ as $\sum_c P(S_c \leq t)$, and for the countries reporting an Alpha sequence, the cumulative distribution of introduction date conditional on submission date, $P(I_c \leq t|S_c)$.

## Autochthonous model A

To simulate the number of Alpha variant infections at the beginning of 2021 in each country of interest, we used the daily rates of importation as estimated from the international dissemination model $\lambda_c^1(t)$) and simulated the subsequent stochastic outcome of each imported infectious individual in the destination country. The different Alpha epidemic clusters initiated by each importation were assumed to be independent. The stochastic epidemic growth model has been described elsewhere (*40*). For each day since $T_0$ and each country of destination, we drew the number of imported infections in a Poisson distribution with rate $\lambda_c^*(t)$. Then, starting with each imported infection, we simulated an epidemic chain assuming that each infected individual produced a number of secondary infections according to a negative binomial distribution with mean $(1 + \alpha)R_t$ and dispersion parameter $\kappa = 0.4$, where $R_t$ is the effective reproduction number at date $t$ and $\alpha = 0.6$ is the transmission advantage of the Alpha variant relative to the historical strain (*41*). The generation time distribution was gamma with mean 6.5 days and s.d. 4 days (shape 2.64, scale 2.46) (*28*). To compute the effective reproduction number $R_t$ of the historical strain from mortality data, we computed first the daily exponential growth rate as $r_t = 1/7 \log(D_{w+1}/D_w)$ where $D_w$ is the number of deaths in week $w$. To account for the lag between disease onset and death (approx. 3 weeks), we considered that this exponential growth rate applied to infections for days $t$ in week $w - 3$. We finally computed

$R_t = \int\limits_0^\infty \exp(-r_t\tau)g(\tau)d\tau$ with $g(\tau)$ the generation interval distribution (*57*). This approach

yielded estimates similar to the Epiestim method (*58*).

In the simulations of epidemic clusters, the code loops over time, starting from one infected individual at the day of importation, and ending at 31 Jan 2021. Time was discretized in time-steps of 0.1 day. The secondary infections are added to their (future) date in the incidence table, and the code proceeds to the next infected individual at this time step, then to the next time-step. Five hundreds (500) replicate simulations were obtained for each country to account for stochastic variability in the number and timing of importations and growth of local epidemics.

Number of infections output of the model were compared to the empirical number cases estimated from the virological survey. Assuming a delay between infection and case detection of one week, empirical cases were compared with model-predicted Alpha infections 7 days before.

## Autochthonous model B

We used a stochastic discrete age-stratified, two-strain transmission model to simulate the epidemic dynamics in France generated by the estimated Alpha importations (*42*, *43*, *59*).

The model integrates data on demography, age profile, social contacts, mobility and adoption of preventive measures. Four age classes are considered: [0–11), [11–19), [19–65) and 65+ years old (children, adolescents, adults and seniors respectively). Transmission dynamics follows a compartmental scheme specific for COVID-19 where individuals are divided into susceptible, exposed, infectious, hospitalized and recovered. The infectious class is further divided into prodromal, asymptomatic and symptomatic. Susceptibility and transmissibility depend on age (*60–62*). Transmissibility also depends on the level of symptoms (*63–66*).

Contact matrices are setting-specific. Contacts at school are modeled according to the French school calendar, while those at work and on transports according to the workplace presence estimated by Google data (*67*). During the different stages of the pandemic, physical contacts are modulated based on surveys on the adoption of physical distancing (*68*), self protection (*42*), and assuming a reduction in contacts due to severe symptoms. The integration of all these data allows for capturing the social distancing restrictions put in place in France to curb the

second wave, namely a lockdown with schools open (*69*) from week 44 (starting October 31, 2020) to week 51 (ending December 15, 2020).

The model was previously used to respond to the COVID-19 pandemic in France in 2020 (*42*, *43*, *70*, *71*), assessing the impact of lockdown (*71*), of night curfew (*43*) and of the reopening of schools (*70*), estimating the underdetection of cases (*42*), and anticipating the impact of the Alpha variant in France (*43*). In particular, we used, here, the same two-strain version of the model developed to study the impact of January 2021 curfew in France on the Alpha circulation in the territory (*43*), with same parametrization and same transmissibility calibrated to national daily hospital admission data (*72*). This accounts for the co-circulation of Alpha variant and the historical strains, and assumes complete cross-immunity between the two strains, higher hospitalization rate and an increase in transmissibility of 50% for Alpha (*27*). We also tested a 60% advantage in transmission, finding that results were robust.

We simulate the epidemic dynamics using the output of the international dissemination model as seeding for the dynamics. At each date, we extract the number of prodromal adults infected with the variant from a Poisson distribution with mean equal to the traveling cases at that date obtained from the international dissemination model. We repeat this extraction for each of the 500 stochastic runs performed and we simulate the resulting outbreak. We then compute the proportion of Alpha on January 8 and compare it with the proportion identified by the first large-scale genome sequencing initiative (called Flash #1) (*41*) conducted in the country on January 7-8, 2021 (Alpha proportion in France equal to 3.3%).

Seeding time of active transmission chains

The time of seeding of a transmission chain still active at a reference end time (time $T_R$) is uniformly distributed over the range of possible introduction times when the exponential growth rate $r$ is the same in the place of origin (here the UK) and in the destination country and traveling flows are constant over time. This is because starting from the date of emergence $T_E$, the number of introductions in the destination country at some time $t_I$ will be proportional to $\exp[r(t_I - T_E)]$ and each case introduced will cause $\exp[r(T_R - t_I)]$ cases at time $T_R$, so that the overall number of cases at time $T_R$ is $\exp[r(t_I - T_E)].\exp[r(T_R - t_I)] = \exp[r(T_R - T_E)]$ irrespective of the actual date of introduction. Therefore, date $(T_E + T_R)/2$ is the expected

median introduction date in this simple scenario of constant exponential growth rate and traveling.

We therefore used the autochthonous model A to reconstruct the distribution of the seeding times for the transmission chains still active on December 31st, 2020. We computed the distribution of seeding times and the difference between the median of this distribution and the expected median under the constant exponential growth rate and traveling described above. The extent of this difference illustrates the effect of the actual change in epidemic growth rate and traveling flows on seeding success. We are here interested on how this quantity changed across the six countries. We found that it increased for lowering values of $R_t$. This show that low values of $R_t$ were likely hindering the seeding of local transmission chains by the introduced cases, making the late importations comparatively more important.

**Acknowledgments**

We gratefully acknowledge all data contributors, i.e., the Authors and their Originating laboratories responsible for obtaining the specimens, and their Submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based.

**Funding:** This study is partially funded by: the Municipality of Paris through the programme Emergence(s) to C.P. and B.F.; the Agence Nationale de la Recherche project DATA- REDUX (ANR-19-CE46-0008-03) to V.C.; ANRS–Maladies Infectieuses Émergentes project EMERGEN (ANRS0151) to V.C.; EU Horizon 2020 grants MOOD (H2020-874850) to V.C., C.P., P.Y.B., M.U.G.K., P.L. and RECOVER (H2020- 101003589) to V.C.; the ERC grant EvoComBac 949208 to F.B.; ERC grant ReservoirDOCS 725422 to P.L.; Institut des Sciences du Calcul et de la Donnée (ISCD).

**Author contribution:** V.C., F.B., C.P., and P.-Y.B. conceived and designed the study. B.F., P.-Y.B., and C.P. developed the international dissemination model. P.C., and F.B., developed the autochthonous model A. C.E.S. and V.C. developed the autochthonous model B. M.U.G.K. and P.L. critically commented on the model ingredients and assumptions. V.C., F.B., C.P., and P.-Y.B wrote the original draft. All authors discussed the results, edited the manuscript, and approved its final version.

**Competing interests:** Authors declare no competing interests.

**Data and materials availability:** The findings of this study are based on metadata associated with a total of 1,735,675 sequences available on GISAID and submitted between 15 Aug 2020 and 1 Jun 2021 included and downloaded on 2 Jun 2021 via gisaid.org (GISAID: EPI_SET_230724tv). To view the contributors of each sequence associated with the metadata we used, visit https://doi.org/10.55876/gis8.230724tv. Proprietary airline data are commercially available from OAG and IATA databases. All other data used in the study are publicly available online at the links provided in the references. Source codes to reproduce the results of this study are publicly shared on GitHub at the link

https://github.com/BenjaminFaucher/Alpha-dissemination/tree/main

## References

1. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological* (2020), (available at https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563).
2. NERVTAG: Meeting on SARS-CoV-2 variant under investigation VUI-202012/01, 18 December 2020. *GOV.UK*, (available at https://www.gov.uk/government/publications/nervtag-meeting-on-sars-cov-2-variant-under-investigation-vui-20201201-18-december-2020).
3. Y. Shu, J. McCauley, GISAID: Global initiative on sharing all influenza data – from vision to reality. *Eurosurveillance*. **22**, 30494 (2017).
4. Á. O'Toole, V. Hill, O. G. Pybus, A. Watts, I. I. Bogoch, K. Khan, J. P. Messina, COVID-19 Genomics UK (COG-UK) consortium, Network for Genomic Surveillance in South Africa (NGS-SA), Brazil-UK CADDE Genomic Network, H. Tegally, R. R. Lessells, J. Giandhari, S. Pillay, K. A. Tumedi, G. Nyepetsi, M. Kebabonye, M. Matsheka, M. Mine, S. Tokajian, H. Hassan, T. Salloum, G. Merhi, J. Koweyes, J. L. Geoghegan, J. de Ligt, X. Ren, M. Storey, N. E. Freed, C. Pattabiraman, P. Prasad, A. S. Desai, R. Vasanthapuram, T. F. Schulz, L. Steinbrück, T. Stadler, Swiss Viollier Sequencing Consortium, A. Parisi, A. Bianco, D. García de Viedma, S. Buenestado-Serrano, V. Borges, J. Isidro, S. Duarte, J. P. Gomes, N. S. Zuckerman, M. Mandelboim, O. Mor, T. Seemann, A. Arnott, J. Draper, M. Gall, W. Rawlinson, I. Deveson, S. Schlebusch, J. McMahon, L. Leong, C. K. Lim, M. Chironna, D. Loconsole, A. Bal, L. Josset, E. Holmes, K. St George, E. Lasek-Nesselquist, R. S. Sikkema, B. Oude Munnink, M. Koopmans, M. Brytting, V. Sudha Rani, S. Pavani, T. Smura, A. Heim, S. Kurkela, M. Umair, M. Salman, B. Bartolini, M. Rueca, C. Drosten, T. Wolff, O. Silander, D. Eggink, C. Reusken, H. Vennema, A. Park, C. Carrington, N. Sahadeo, M. Carr, G. Gonzalez, SEARCH Alliance San Diego, National Virus Reference Laboratory, SeqCOVID-Spain, Danish Covid-19 Genome Consortium (DCGC), Communicable Diseases Genomic Network (CDGN), Dutch National SARS-CoV-2 surveillance program, Division of Emerging Infectious Diseases (KDCA), T. de Oliveira, N. Faria, A. Rambaut, M. U. G. Kraemer, Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch. *Wellcome Open Res*. **6**, 121 (2021).

5.  Z. Du, L. Wang, B. Yang, S. T. Ali, T. K. Tsang, S. Shan, P. Wu, E. H. Y. Lau, B. J. Cowling, L. A. Meyers, Risk for International Importations of Variant SARS-CoV-2 Originating in the United Kingdom. *Emerg Infect Dis*. **27**, 1527–1529 (2021).

6.  M. Chinazzi, J. T. Davis, K. Mu, N. Perra, S. V. Scarpino, A. Vespignani, Preliminary estimates of the international spreading risk associated with the SARS-CoV-2 VUI 202012/0.

7.  S. Lai, J. Floyd, A. Tatem, Preliminary risk analysis of the international spread of new COVID-19 variants, lineage B.1.1.7, B.1.351 and P.

8.  SPF, COVID-19 : point épidémiologique du 28 janvier 2021, (available at https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-28-janvier-2021).

9.  C. Chen, S. A. Nadeau, I. Topolsky, M. Manceau, J. S. Huisman, K. P. Jablonski, L. Fuhrmann, D. Dreifuss, K. Jahn, C. Beckmann, M. Redondo, C. Noppen, L. Risch, M. Risch, N. Wohlwend, S. Kas, T. Bodmer, T. Roloff, M. Stange, A. Egli, I. Eckerle, L. Kaiser, R. Denes, M. Feldkamp, I. Nissen, N. Santacroce, E. Burcklen, C. Aquino, A. C. de Gouvea, M. D. Moccia, S. Grüter, T. Sykes, L. Opitz, G. White, L. Neff, D. Popovic, A. Patrignani, J. Tracy, R. Schlapbach, E. T. Dermitzakis, K. Harshman, I. Xenarios, H. Pegeot, L. Cerutti, D. Penet, A. Blin, M. Elies, C. L. Althaus, C. Beisel, N. Beerenwinkel, M. Ackermann, T. Stadler, Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. *Epidemics*. **37**, 100480 (2021).

10. N. L. Washington, K. Gangavarapu, M. Zeller, A. Bolze, E. T. Cirulli, K. M. Schiabor Barrett, B. B. Larsen, C. Anderson, S. White, T. Cassens, S. Jacobs, G. Levan, J. Nguyen, J. M. Ramirez, C. Rivera-Garcia, E. Sandoval, X. Wang, D. Wong, E. Spencer, R. Robles-Sikisaka, E. Kurzban, L. D. Hughes, X. Deng, C. Wang, V. Servellita, H. Valentine, P. De Hoff, P. Seaver, S. Sathe, K. Gietzen, B. Sickler, J. Antico, K. Hoon, J. Liu, A. Harding, O. Bakhtar, T. Basler, B. Austin, D. MacCannell, M. Isaksson, P. G. Febbo, D. Becker, M. Laurent, E. McDonald, G. W. Yeo, R. Knight, L. C. Laurent, E. de Feo, M. Worobey, C. Y. Chiu, M. A. Suchard, J. T. Lu, W. Lee, K. G. Andersen, Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell*. **184**, 2587-2594.e7 (2021).

11. T. Alpert, A. F. Brito, E. Lasek-Nesselquist, J. Rothman, A. L. Valesano, M. J. MacKay, M. E. Petrone, M. I. Breban, A. E. Watkins, C. B. F. Vogels, C. C. Kalinich, S. Dellicour, A. Russell, J. P. Kelly, M. Shudt, J. Plitnick, E. Schneider, W. J. Fitzsimmons, G. Khullar, J. Metti, J. T. Dudley, M. Nash, N. Beaubier, J. Wang, C. Liu, P. Hui, A. Muyombwe, R. Downing, J. Razeq, S. M. Bart, A. Grills, S. M. Morrison, S. Murphy, C. Neal, E. Laszlo, H. Rennert, M. Cushing, L. Westblade, P. Velu, A. Craney, L. Cong, D. R. Peaper, M. L. Landry, P. W. Cook, J. R. Fauver, C. E. Mason, A. S. Lauring, K. St. George, D. R. MacCannell, N. D. Grubaugh, Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. *Cell*. **184**, 2595-2604.e13 (2021).

12. R. Niehus, P. M. De Salazar, A. R. Taylor, M. Lipsitch, Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China. *The Lancet Infectious Diseases*. **20**, 803–808 (2020).

13. F. Pinotti, L. D. Domenico, E. Ortega, M. Mancastroppa, G. Pullano, E. Valdano, P.-Y. Boëlle, C. Poletto, V. Colizza, Tracing and analysis of 288 early SARS-CoV-2 infections outside China: A modeling study. *PLOS Medicine*. **17**, e1003193 (2020).

14. J. T. Davis, M. Chinazzi, N. Perra, K. Mu, A. Pastore y Piontti, M. Ajelli, N. E. Dean, C. Gioannini, M. Litvinova, S. Merler, L. Rossi, K. Sun, X. Xiong, I. M. Longini, M. E. Halloran, C. Viboud, A. Vespignani, Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. *Nature*. **600**, 127–132 (2021).

15. T. Bedford, A. L. Greninger, P. Roychoudhury, L. M. Starita, M. Famulare, M.-L. Huang, A. Nalla, G. Pepper, A. Reinhardt, H. Xie, L. Shrestha, T. N. Nguyen, A. Adler, E. Brandstetter,

S. Cho, D. Giroux, P. D. Han, K. Fay, C. D. Frazar, M. Ilcisin, K. Lacombe, J. Lee, A. Kiavand, M. Richardson, T. R. Sibley, M. Truong, C. R. Wolf, D. A. Nickerson, M. J. Rieder, J. A. Englund, The Seattle Flu Study Investigators, J. Hadfield, E. B. Hodcroft, J. Huddleston, L. H. Moncla, N. F. Müller, R. A. Neher, X. Deng, W. Gu, S. Federman, C. Chiu, J. S. Duchin, R. Gautom, G. Melly, B. Hiatt, P. Dykema, S. Lindquist, K. Queen, Y. Tao, A. Uehara, S. Tong, D. MacCannell, G. L. Armstrong, G. S. Baird, H. Y. Chu, J. Shendure, K. R. Jerome, Cryptic transmission of SARS-CoV-2 in Washington state. *Science*. **370**, 571–575 (2020).

16. M. Worobey, J. Pekar, B. B. Larsen, M. I. Nelson, V. Hill, J. B. Joy, A. Rambaut, M. A. Suchard, J. O. Wertheim, P. Lemey, The emergence of SARS-CoV-2 in Europe and North America. *Science*. **370**, 564–570 (2020).

17. P. Lemey, S. L. Hong, V. Hill, G. Baele, C. Poletto, V. Colizza, Á. O'Toole, J. T. McCrone, K. G. Andersen, M. Worobey, M. I. Nelson, A. Rambaut, M. A. Suchard, Accommodating individual travel history and unsampled diversity in Bayesian phylogeographic inference of SARS-CoV-2. *Nat Commun*. **11**, 5110 (2020).

18. J. T. McCrone, V. Hill, S. Bajaj, R. E. Pena, B. C. Lambert, R. Inward, S. Bhatt, E. Volz, C. Ruis, S. Dellicour, G. Baele, A. E. Zarebski, A. Sadilek, N. Wu, A. Schneider, X. Ji, J. Raghwani, B. Jackson, R. Colquhoun, Á. O'Toole, T. P. Peacock, K. Twohig, S. Thelwall, G. Dabrera, R. Myers, N. R. Faria, C. Huber, I. I. Bogoch, K. Khan, L. du Plessis, J. C. Barrett, D. M. Aanensen, W. S. Barclay, M. Chand, T. Connor, N. J. Loman, M. A. Suchard, O. G. Pybus, A. Rambaut, M. U. G. Kraemer, Context-specific emergence and growth of the SARS-CoV-2 Delta variant. *Nature*. **610**, 154–160 (2022).

19. H. Tegally, E. Wilkinson, J. L.-H. Tsui, M. Moir, D. Martin, A. F. Brito, M. Giovanetti, K. Khan, C. Huber, I. I. Bogoch, J. E. San, J. Poongavanan, J. S. Xavier, D. da S. Candido, F. Romero, C. Baxter, O. G. Pybus, R. J. Lessells, N. R. Faria, M. U. G. Kraemer, T. de Oliveira, Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern. *Cell*. **186**, 3277-3290.e16 (2023).

20. J. L.-H. Tsui, J. T. McCrone, B. Lambert, S. Bajaj, R. P. D. Inward, P. Bosetti, R. E. Pena, H. Tegally, V. Hill, A. E. Zarebski, T. P. Peacock, L. Liu, N. Wu, M. Davis, I. I. Bogoch, K. Khan, M. Kall, N. I. B. Abdul Aziz, R. Colquhoun, Á. O'Toole, B. Jackson, A. Dasgupta, E. Wilkinson, T. de Oliveira, The COVID-19 Genomics UK (COG-UK) consortium, T. R. Connor, N. J. Loman, V. Colizza, C. Fraser, E. Volz, X. Ji, B. Gutierrez, M. Chand, S. Dellicour, S. Cauchemez, J. Raghwani, M. A. Suchard, P. Lemey, A. Rambaut, O. G. Pybus, M. U. G. Kraemer, Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1. *Science*. **381**, 336–343 (2023).

21. A. J. Kucharski, M. Jit, J. G. Logan, M. Cotten, S. Clifford, B. J. Quilty, T. W. Russell, R. W. Peeling, M. Antonio, D. L. Heymann, Travel measures in the SARS-CoV-2 variant era need clear objectives. *The Lancet*. **399**, 1367–1369 (2022).

22. A. F. Brito, E. Semenova, G. Dudas, G. W. Hassler, C. C. Kalinich, M. U. G. Kraemer, J. Ho, H. Tegally, G. Githinji, C. N. Agoti, L. E. Matkin, C. Whittaker, B. P. Howden, V. Sintchenko, N. S. Zuckerman, O. Mor, H. M. Blankenship, T. de Oliveira, R. T. P. Lin, M. M. Siqueira, P. C. Resende, A. T. R. Vasconcelos, F. R. Spilki, R. S. Aguiar, I. Alexiev, I. N. Ivanov, I. Philipova, C. V. F. Carrington, N. S. D. Sahadeo, B. Branda, C. Gurry, S. Maurer-Stroh, D. Naidoo, K. J. von Eije, M. D. Perkins, M. van Kerkhove, S. C. Hill, E. C. Sabino, O. G. Pybus, C. Dye, S. Bhatt, S. Flaxman, M. A. Suchard, N. D. Grubaugh, G. Baele, N. R. Faria, Global disparities in SARS-CoV-2 genomic surveillance. *Nat Commun*. **13**, 7003 (2022).

23. T. S. Brett, P. Rohani, Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing. *PNAS Nexus*. **1**, pgac159 (2022).

24. Z. Susswein, K. E. Johnson, R. Kassa, M. Parastaran, V. Peng, L. Wolansky, S. V. Scarpino, A. I. Bento, Leveraging global genomic sequencing data to estimate local variant dynamics (2023), p. 2023.01.02.23284123, , doi:10.1101/2023.01.02.23284123.

25. P. P. Klamser, V. d'Andrea, F. Di Lauro, A. Zachariae, S. Bontorin, A. Di Nardo, M. Hall, B. F. Maier, L. Ferretti, D. Brockmann, M. De Domenico, Enhancing global preparedness during an ongoing pandemic from partial and noisy data. *PNAS Nexus*. **2**, pgad192 (2023).

26. A. X. Han, A. Toporowski, J. A. Sacks, M. D. Perkins, S. Briand, M. van Kerkhove, E. Hannay, S. Carmona, B. Rodriguez, E. Parker, B. E. Nichols, C. A. Russell, SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs. *Nat Genet*. **55**, 26–33 (2023).

27. N. G. Davies, S. Abbott, R. C. Barnard, C. I. Jarvis, A. J. Kucharski, J. D. Munday, C. A. B. Pearson, T. W. Russell, D. C. Tully, A. D. Washburne, T. Wenseleers, A. Gimma, W. Waites, K. L. M. Wong, K. van Zandvoort, J. D. Silverman, CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, K. Diaz-Ordaz, R. Keogh, R. M. Eggo, S. Funk, M. Jit, K. E. Atkins, W. J. Edmunds, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. **372**, eabg3055 (2021).

28. E. Volz, S. Mishra, M. Chand, J. C. Barrett, R. Johnson, L. Geidelberg, W. R. Hinsley, D. J. Laydon, G. Dabrera, Á. O'Toole, R. Amato, M. Ragonnet-Cronin, I. Harrison, B. Jackson, C. V. Ariani, O. Boyd, N. J. Loman, J. T. McCrone, S. Gonçalves, D. Jorgensen, R. Myers, V. Hill, D. K. Jackson, K. Gaythorpe, N. Groves, J. Sillitoe, D. P. Kwiatkowski, S. Flaxman, O. Ratmann, S. Bhatt, S. Hopkins, A. Gandy, A. Rambaut, N. M. Ferguson, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. **593**, 266–269 (2021).

29. M. U. G. Kraemer, V. Hill, C. Ruis, S. Dellicour, S. Bajaj, J. T. McCrone, G. Baele, K. V. Parag, A. L. Battle, B. Gutierrez, B. Jackson, R. Colquhoun, Á. O'Toole, B. Klein, A. Vespignani, E. Volz, N. R. Faria, D. M. Aanensen, N. J. Loman, L. du Plessis, S. Cauchemez, A. Rambaut, S. V. Scarpino, O. G. Pybus, Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. *Science*. **373**, 889–895 (2021).

30. Sequencing of SARS-CoV-2 - first update (2021), (available at https://www.ecdc.europa.eu/en/publications-data/sequencing-sars-cov-2).

31. Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA (2020), (available at https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-sars-cov-2-variants-eueea).

32. L. du Plessis, J. T. McCrone, A. E. Zarebski, V. Hill, C. Ruis, B. Gutierrez, J. Raghwani, J. Ashworth, R. Colquhoun, T. R. Connor, N. R. Faria, B. Jackson, N. J. Loman, Á. O'Toole, S. M. Nicholls, K. V. Parag, E. Scher, T. I. Vasylyeva, E. M. Volz, A. Watts, I. I. Bogoch, K. Khan, COVID-19 Genomics UK (COG-UK) Consortium, D. M. Aanensen, M. U. G. Kraemer, A. Rambaut, O. G. Pybus, Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science*. **371**, 708–712 (2021).

33. S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittaker, H. Zhu, T. Berah, J. W. Eaton, M. Monod, A. C. Ghani, C. A. Donnelly, S. Riley, M. A. C. Vollmer, N. M. Ferguson, L. C. Okell, S. Bhatt, Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. **584**, 257–261 (2020).

34. Lineage-specific growth of SARS-CoV-2 B.1.1.7 during the English national lockdown. *Virological* (2020), (available at https://virological.org/t/lineage-specific-growth-of-sars-cov-2-b-1-1-7-during-the-english-national-lockdown/575).

35. V. Hill, L. Du Plessis, T. P. Peacock, D. Aggarwal, R. Colquhoun, A. M. Carabelli, N. Ellaby, E. Gallagher, N. Groves, B. Jackson, J. T. McCrone, Á. O'Toole, A. Price, T. Sanderson, E. Scher, J. Southgate, E. Volz, W. S. Barclay, J. C. Barrett, M. Chand, T. Connor, I. Goodfellow, R. K. Gupta, E. M. Harrison, N. Loman, R. Myers, D. L. Robertson, O. G. Pybus, A. Rambaut, The COVID-19 Genomics UK (COG-UK) Consortium, The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. *Virus Evolution*. **8**, veac080 (2022).

36. Public Health England, SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 7, (available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972247/Variants_of_Concern_VOC_Technical_Briefing_7_England.pdf).

37. T. Y. Michaelsen, M. Bennedbæk, L. E. Christiansen, M. S. F. Jørgensen, C. H. Møller, E. A. Sørensen, S. Knutsson, J. Brandt, T. B. N. Jensen, C. Chiche-Lapierre, E. F. Collados, T. Sørensen, C. Petersen, V. Le-Quy, M. Sereika, F. T. Hansen, M. Rasmussen, J. Fonager, S. M. Karst, R. L. Marvig, M. Stegger, R. N. Sieber, R. Skov, R. Legarth, T. G. Krause, A. Fomsgaard, K. S. Andersen, M. H. Andersen, A. Berg, S. R. Bielidt, S. M. Dall, E. Dvarionaite, S. H. Hansen, V. R. Jørgensen, R. H. Kirkegaard, W. Saei, T. B. Nicolajsen, S. K. Østergaard, R. F. Brøndum, M. Bøgsted, K. Hose, T. Sagi, M. Pakanec, D. Fuglsang-Damgaard, M. Mølvadgaard, H. Krarup, C. W. Svarrer, M. T. Christiansen, A. C. Ingham, T. B. Johannesen, M. Basterrechea, B. Lilje, K. Ellegaard, P. Matusevicius, L. B. Christoffersen, M.-H. E. Tang, K. L. Ng, S. M. Edslev, S. Baig, O. H. Larsen, K. A. Skipper, S. Vang, K. J. Handberg, M. T. K. Nielsen, C. M. Kobel, C. Andersen, I. H. Tarpgaard, S. Ellermann-Eriksen, J. A. S. Castruita, U. V. Schneider, N. G. Jacobsen, C. Ø. Andersen, M. S. Pedersen, K. Schønning, N. Kirkby, L. Nielsen, L. L. Nilsson, M. B. Friis, T. Sundelin, T. A. Hansen, M. N. Skov, T. V. Sydenham, X. C. Nielsen, C. H. Schouw, A. Jensen, E. S. Marmolin, J. E. Coia, D. T. Andersen, M. Albertsen, The Danish COVID-19 Genome Consortium (DCGC), Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark. *Genome Medicine*. **14**, 47 (2022).

38. A. Chaillon, D. M. Smith, Phylogenetic Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 Lineage Suggest a Single Origin Followed by Multiple Exportation Events Versus Convergent Evolution. *Clinical Infectious Diseases*. **73**, 2314–2317 (2021).

39. Phylogenetic evidence that B.1.1.7 has been circulating in the United States since early- to mid-November. *Virological* (2021), (available at https://virological.org/t/phylogenetic-evidence-that-b-1-1-7-has-been-circulating-in-the-united-states-since-early-to-mid-november/598).

40. P. Czuppon, E. Schertzer, F. Blanquart, F. Débarre, The stochastic dynamics of early epidemics: probability of establishment, initial growth rate, and infection cluster size at first detection. *Journal of The Royal Society Interface*. **18**, 20210575 (2021).

41. A. Gaymard, P. Bosetti, A. Feri, G. Destras, V. Enouf, A. Andronico, S. Burrel, S. Behillil, C. Sauvage, A. Bal, F. Morfin, S. V. D. Werf, L. Josset, A. M. A. Covid-19, F. viro C. Group, F. Blanquart, B. Coignard, S. Cauchemez, B. Lina, Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Eurosurveillance*. **26**, 2100133 (2021).

42. G. Pullano, L. Di Domenico, C. E. Sabbatini, E. Valdano, C. Turbelin, M. Debin, C. Guerrisi, C. Kengne-Kuetche, C. Souty, T. Hanslik, T. Blanchon, P.-Y. Boëlle, J. Figoni, S. Vaux, C. Campèse, S. Bernard-Stoecklin, V. Colizza, Underdetection of cases of COVID-19 in France threatens epidemic control. *Nature*. **590**, 134–139 (2021).

43. L. D. Domenico, C. E. Sabbatini, G. Pullano, D. Lévy-Bruhl, V. Colizza, Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France. *Eurosurveillance*. **26**, 2100272 (2021).

44. C. Poletto, M. F. Gomes, A. P. y Piontti, L. Rossi, L. Bioglio, D. L. Chao, I. M. L. Jr, M. E. Halloran, V. Colizza, A. Vespignani, Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. *Eurosurveillance*. **19**, 20936 (2014).

45. C. Poletto, P.-Y. Boëlle, V. Colizza, Risk of MERS importation and onward transmission: a systematic review and analysis of cases reported to WHO. *BMC Infectious Diseases*. **16**, 448 (2016).

46. A. Gautreau, A. Barrat, M. Barthélemy, Global disease spread: Statistics and estimation of arrival times. *Journal of Theoretical Biology*. **251**, 509–522 (2008).
47. G. Scalia Tomba, J. Wallinga, A simple explanation for the low impact of border control as a countermeasure to the spread of an infectious disease. *Mathematical Biosciences*. **214**, 70–72 (2008).
48. D. Brockmann, D. Helbing, The Hidden Geometry of Complex, Network-Driven Contagion Phenomena. *Science*. **342**, 1337–1342 (2013).
49. E. B. Hodcroft, M. Zuber, S. Nadeau, T. G. Vaughan, K. H. D. Crawford, C. L. Althaus, M. L. Reichmuth, J. E. Bowen, A. C. Walls, D. Corti, J. D. Bloom, D. Veesler, D. Mateo, A. Hernando, I. Comas, F. González-Candelas, T. Stadler, R. A. Neher, Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *Nature*. **595**, 707–712 (2021).
50. M. U. G. Kraemer, O. G. Pybus, C. Fraser, S. Cauchemez, A. Rambaut, B. J. Cowling, Monitoring key epidemiological parameters of SARS-CoV-2 transmission. *Nat Med*. **27**, 1854–1855 (2021).
51. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases*. **20**, 533–534 (2020).
52. Data on 14-day notification rate of new COVID-19 cases and deaths (2023), (available at https://www.ecdc.europa.eu/en/publications-data/data-national-14-day-notification-rate-covid-19).
53. IATA, (available at https://www.iata.org/en/).
54. Eurotunnel - Trafic Navettes du mois de décembre 2020. *Eurotunnel Le Shuttle*, (available at https://www.eurotunnelfreight.com/fr/2021/01/trafic-navettes-du-mois-de-decembre-2020/).
55. Sea passenger statistics: data tables (SPAS). *GOV.UK* (2023), (available at https://www.gov.uk/government/statistical-data-sets/sea-passenger-statistics-spas).
56. E. Colman, G. A. Puspitarani, J. Enright, R. R. Kao, Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK. *Journal of Theoretical Biology*. **558**, 111333 (2023).
57. J. Wallinga, M. Lipsitch, How generation intervals shape the relationship between growth rates and reproductive numbers. *Proceedings of the Royal Society B: Biological Sciences*. **274**, 599–604 (2006).
58. A. Cori, N. M. Ferguson, C. Fraser, S. Cauchemez, A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics. *American Journal of Epidemiology*. **178**, 1505–1512 (2013).
59. L. Di Domenico, C. E. Sabbatini, P.-Y. Boëlle, C. Poletto, P. Crépey, J. Paireau, S. Cauchemez, F. Beck, H. Noel, D. Lévy-Bruhl, V. Colizza, Adherence and sustainability of interventions informing optimal control against the COVID-19 pandemic. *Commun Med*. **1**, 1–13 (2021).
60. R. M. Viner, O. T. Mytton, C. Bonell, G. J. Melendez-Torres, J. Ward, L. Hudson, C. Waddington, J. Thomas, S. Russell, F. van der Klis, A. Koirala, S. Ladhani, J. Panovska-Griffiths, N. G. Davies, R. Booy, R. M. Eggo, Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics*. **175**, 143–156 (2021).
61. H. A. Thompson, A. Mousa, A. Dighe, H. Fu, A. Arnedo-Pena, P. Barrett, J. Bellido-Blasco, Q. Bi, A. Caputi, L. Chaw, L. De Maria, M. Hoffmann, K. Mahapure, K. Ng, J. Raghuram, G. Singh, B. Soman, V. Soriano, F. Valent, L. Vimercati, L. E. Wee, J. Wong, A. C. Ghani, N. M. Ferguson, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*. **73**, e754–e764 (2021).
62. A. Fontanet, L. Tondeur, R. Grant, S. Temmam, Y. Madec, T. Bigot, L. Grzelak, I. Cailleau, C. Besombes, M.-N. Ungeheuer, C. Renaudat, B. L. Perlaza, L. Arowas, N. Jolly, S. F.

Pellerin, L. Kuhmel, I. Staropoli, C. Huon, K.-Y. Chen, B. Crescenzo-Chaigne, S. Munier, P. Charneau, C. Demeret, T. Bruel, M. Eloit, O. Schwartz, B. Hoen, SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. *Eurosurveillance*. **26**, 2001695 (2021).

63. R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*. **368**, 489–493 (2020).

64. X. Qiu, A. I. Nergiz, A. E. Maraolo, I. I. Bogoch, N. Low, M. Cevik, The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review. *Clinical Microbiology and Infection*. **27**, 511–519 (2021).

65. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine*. **17**, e1003346 (2020).

66. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China: A Prospective Cohort Study: Annals of Internal Medicine: Vol 173, No 11, (available at https://www.acpjournals.org/doi/full/10.7326/M20-2671).

67. google mobility data - Recherche Google, (available at https://www.google.com/search?q=google+mobility+data&oq=google+mobility+data&aqs=chrome..69i57j0i22i30l9.3715j0j4&sourceid=chrome&ie=UTF-8).

68. CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé mentale pendant l'épidémie de COVID-19, (available at https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19).

69. G. Pullano, L. D. Domenico, C. E. Sabbatini, V. Colizza, Expected impact of a lockdown with schools in session - France, Nov 2020.

70. L. Di Domenico, G. Pullano, C. E. Sabbatini, P.-Y. Boëlle, V. Colizza, Modelling safe protocols for reopening schools during the COVID-19 pandemic in France. *Nat Commun*. **12**, 1073 (2021).

71. L. Di Domenico, G. Pullano, C. E. Sabbatini, P.-Y. Boëlle, V. Colizza, Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. *BMC Medicine*. **18**, 240 (2020).

72. Données hospitalières relatives à l'épidémie de COVID-19 (SIVIC) - data.gouv.fr, (available at https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/).